Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1675
    +0.0018 (+0.16%)
     
  • GBP/USD

    1.2488
    -0.0023 (-0.19%)
     
  • Bitcoin GBP

    51,007.36
    -570.16 (-1.11%)
     
  • CMC Crypto 200

    1,324.80
    -71.73 (-5.13%)
     
  • S&P 500

    5,110.27
    +61.85 (+1.23%)
     
  • DOW

    38,300.09
    +214.29 (+0.56%)
     
  • CRUDE OIL

    83.91
    +0.34 (+0.41%)
     
  • GOLD FUTURES

    2,346.10
    +3.60 (+0.15%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

1 Reason to Sell Novavax Stock, and 1 Reason to Buy

This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.